Table 2.

Mothers reporting exclusive, mixed, or no breastfeeding during study intervals by group

	Maternal antiretroviral			Infant nevirapine			Control			p value
	Exclusive breastfeeding	Mixed breastfeeding	No breastfeeding	Exclusive breast feeding†	Mixed breastfeeding	No breastfeeding	Exclusive breastfeeding	Mixed breastfeeding	No breastfeeding
13–18 weeks	615/630 (98%)	12/630 (2%)	3/630 (<1%)	665/676 (98%)	8/676 (1%)	3/676 (<1%)	471/480 (98%)	6/480 (1%)	3/480 (<1%)	0·9177
19–21 weeks	594/618 (96%)	13/618 (2%)	11/618 (2%)	644/662 (97%)	14/662 (2%)	4/662 (<1%)	434/453 (96%)	15/453 (3%)	4/453 (<1%)	0·1420
22–24 weeks	543/612 (89%)	38/612 (6%)	31/612 (5%)	581/643 (90%)	33/643 (5%)	29/643 (5%)	387/440 (88%)	33/440 (8%)	20/440 (5%)	0·8765
25–28 weeks	44/599 (7%)	149/599 (25%)	406/599 (68%)	57/638 (9%)	151/638 (24%)	430/638 (67%)	24/439 (5%)	120/439 (27%)	295/439 (67%)	0·9796
29–32 weeks	1/564 (<1%)	22/564 (4%)	541/564 (96%)	1/591 (<1%)	22/591 (4%)	568/591 (96%)	3/406 (<1%)	45/406 (11%)	358/406 (88%)	<0·0001
33–36 weeks	1/76 (1%)	2/76 (3%)	73/76 (96%)	0/85	3/85 (4%)	82/85 (96%)	0/78	5/78 (6%)	73/78 (94%)	0·7374
37–42 weeks	0/547 (<1%)	21/547 (4%)	526/547 (96%)	1/574 (<1%)	13/574 (2%)	560/574 (98%)	2/405 (<1%)	18/405 (4%)	385/405 (95%)	0·1023
43–48 weeks	1/552 (<1%)	17/552 (3%)	534/552 (97%)	2/574 (<1%)	12/574 (2%)	560/574 (98%)	1/389 (<1%)	16/389 (4%)	372/389 (96%)	0·2448

Data are n/N (%). At each study visit, women were asked how they had fed their child since the previous visit; thus, the data from 13–18 weeks were reported at the 18-week visit and show infant feeding method since the 12-week visit.